Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pratley

Showing results (11-20 of 69) with videos related to

Pageof 7
Sort By:
Diabetes Care|May 7, 2024
Impaired Awareness of Hypoglycemia in Older Adults With Type 1 Diabetes: A Post Hoc Analysis of the WISDM StudyAnika Bilal, Fanchao Yi, Keri Whitaker, et al.
Diabetes, Obesity & Metabolism|March 25, 2021
Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetesJohn B Buse, Ingrid Holst, Filip K Knop, et al.
Diabetologia|September 12, 2014
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylureaPeter N Weissman, Molly C Carr, June Ye, et al.
Diabetes Technology & Therapeutics|March 5, 2024
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with SotagliflozinSchafer Boeder, Michael J Davies, Janet B McGill, et al.
Diabetes, Obesity & Metabolism|January 26, 2023
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmesVanita R Aroda, Umut Erhan, Peter Jelnes, et al.
The Journal of Clinical Endocrinology and Metabolism|May 19, 2023
New-Onset Diabetes After COVID-19Sun H Kim, Ipsa Arora, Daniel S Hsia, et al.
Journal of Diabetes and Its Complications|June 21, 2016
LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes populationIlhan Satman, Rosangela R Rea, Mats Eriksson, et al.
American Journal of Preventive Cardiology|August 31, 2023
Glycemic and metabolic sub-classification of prediabetes and risk factors for cardiovascular disease in the D2d cohortSangeeta R Kashyap, Cyrus Desouza, Vanita R Aroda, et al.
Lancet (London, England)|June 13, 2019
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trialRichard Pratley, Aslam Amod, Søren Tetens Hoff, et al.
The Lancet. Diabetes & Endocrinology|June 14, 2019
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trialOfri Mosenzon, Thalia Marie Blicher, Signe Rosenlund, et al.
Pageof 7

Showing results (11-20 of 69) with videos related to

Sort By:
Pageof 7
Diabetes Care|May 7, 2024
Impaired Awareness of Hypoglycemia in Older Adults With Type 1 Diabetes: A Post Hoc Analysis of the WISDM StudyAnika Bilal, Fanchao Yi, Keri Whitaker, et al.
Diabetes, Obesity & Metabolism|March 25, 2021
Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetesJohn B Buse, Ingrid Holst, Filip K Knop, et al.
Diabetologia|September 12, 2014
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylureaPeter N Weissman, Molly C Carr, June Ye, et al.
Diabetes Technology & Therapeutics|March 5, 2024
Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with SotagliflozinSchafer Boeder, Michael J Davies, Janet B McGill, et al.
Diabetes, Obesity & Metabolism|January 26, 2023
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmesVanita R Aroda, Umut Erhan, Peter Jelnes, et al.
The Journal of Clinical Endocrinology and Metabolism|May 19, 2023
New-Onset Diabetes After COVID-19Sun H Kim, Ipsa Arora, Daniel S Hsia, et al.
Journal of Diabetes and Its Complications|June 21, 2016
LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes populationIlhan Satman, Rosangela R Rea, Mats Eriksson, et al.
American Journal of Preventive Cardiology|August 31, 2023
Glycemic and metabolic sub-classification of prediabetes and risk factors for cardiovascular disease in the D2d cohortSangeeta R Kashyap, Cyrus Desouza, Vanita R Aroda, et al.
Lancet (London, England)|June 13, 2019
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trialRichard Pratley, Aslam Amod, Søren Tetens Hoff, et al.
The Lancet. Diabetes & Endocrinology|June 14, 2019
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trialOfri Mosenzon, Thalia Marie Blicher, Signe Rosenlund, et al.
Pageof 7